The post says pharmaceutical companies directed resources toward oral semaglutide and tirzepatide tablets rather than transdermal systems, because those provide more stable absorption profiles and easier dose titration compared with patches that must overcome skin variation and patient adherence challenges
Beyond that, it can start to lose its effectiveness and it can happen even if the medication itself still looks fine
This tells me there is a mechanism aside from weight loss that drives this improvement. The researchers noted that 42% of patients had been on more than one GLP1-RA medication, without overlap, with liraglutide being most commonly prescribed, followed by semaglutide (Ozempic/Wegovy, Novo Nordisk), dulaglutide (Trulicity, Lilly) and exenatide (Bydureon, AstraZeneca)
The review further suggested that melanocortin receptor activation [may modulate] cellular resilience through modulation of redox sensitive pathways and pigment associated sequestration processes. These hypotheses were presented as exploratory and largely inferential, relying on mechanistic overlap rather than direct experimental validation
Get your sample now to see our research methodology and insights
